Baader Bank Aktiengesellschaft Increases Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Baader Bank Aktiengesellschaft lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 208.4% during the 4th quarter, HoldingsChannel reports. The fund owned 10,844 shares of the biopharmaceutical company’s stock after acquiring an additional 7,328 shares during the period. Baader Bank Aktiengesellschaft’s holdings in Gilead Sciences were worth $1,002,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Foster & Motley Inc. grew its position in shares of Gilead Sciences by 80.4% during the fourth quarter. Foster & Motley Inc. now owns 10,587 shares of the biopharmaceutical company’s stock worth $978,000 after buying an additional 4,718 shares in the last quarter. Swedbank AB boosted its holdings in Gilead Sciences by 2.7% in the fourth quarter. Swedbank AB now owns 2,101,969 shares of the biopharmaceutical company’s stock worth $194,159,000 after purchasing an additional 54,360 shares during the period. Strategic Blueprint LLC boosted its holdings in Gilead Sciences by 7.5% in the fourth quarter. Strategic Blueprint LLC now owns 2,750 shares of the biopharmaceutical company’s stock worth $254,000 after purchasing an additional 192 shares during the period. Asset Dedication LLC boosted its holdings in Gilead Sciences by 43.3% in the fourth quarter. Asset Dedication LLC now owns 6,421 shares of the biopharmaceutical company’s stock worth $593,000 after purchasing an additional 1,940 shares during the period. Finally, Twelve Points Wealth Management LLC acquired a new position in Gilead Sciences in the fourth quarter worth $611,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares in the company, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 456,234 shares of company stock valued at $42,130,461. 0.16% of the stock is currently owned by insiders.

Analysts Set New Price Targets

GILD has been the subject of several analyst reports. Leerink Partners raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $74.00 to $96.00 in a report on Monday, October 21st. Cantor Fitzgerald restated a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Daiwa America raised shares of Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Wolfe Research began coverage on shares of Gilead Sciences in a research note on Friday, November 15th. They issued an “outperform” rating and a $110.00 price objective on the stock. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $98.39.

Gilead Sciences Stock Up 1.9 %

Shares of NASDAQ GILD opened at $95.59 on Thursday. The firm’s 50-day simple moving average is $92.00 and its 200 day simple moving average is $85.44. The company has a market cap of $119.13 billion, a price-to-earnings ratio of 1,062.11, a price-to-earnings-growth ratio of 1.31 and a beta of 0.18. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.90.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the previous year, the business posted $2.29 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.